Certain genetic variations that may help predict survival in cancer patients have been identified by researchers from University of Minnesota.
A research team led by Brian Van Ness, Ph.D, from Masonic Cancer Centre, University of Minnesota, claim to have identified combinations of genes associated with early clinical relapse of multiple myeloma, a cancer of the white blood cells that produce antibodies, which can help predict patient's response to treatment.
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades.
Advertisement
"Ultimately, the goal of this research is to predict drug efficacy and toxicity based on a patient's genetic profile, and develop individualized assessments and predictions for the right drug, at the right dose, for the right patient," said Van Ness.
"This approach offers the dual benefits of avoiding unnecessary treatment for patients less likely to respond to a particular drug, and targeting treatments to those who will benefit most," he added.
![Biopsy-Introduction]( "Biopsy-Introduction")
For the study, Van Ness and his colleagues analysed the genetic information that the International Myeloma Foundation has gathered from myeloma patients worldwide through its program, Bank On A Cure(r).
"Although myeloma is considered a fatal disease, individual patients have widely varied rates of disease progression and response to treatment because of attributes encoded in their DNA," said Van Ness.
According to Van Ness, the research study findings demonstrate that cancer outcomes differ because patients vary in the ways they absorb, distribute, metabolize, and transport drugs across cell membranes.
Individual variations in genes that regulate these biologic processes may not only affect the effectiveness of the drug, but also can result in adverse side effects.
The findings are reported in the current issue of the research journal BMC Medicine.
Source: ANI
RAS/SK
Advertisement
For the study, Van Ness and his colleagues analysed the genetic information that the International Myeloma Foundation has gathered from myeloma patients worldwide through its program, Bank On A Cure(r).
"Although myeloma is considered a fatal disease, individual patients have widely varied rates of disease progression and response to treatment because of attributes encoded in their DNA," said Van Ness.
According to Van Ness, the research study findings demonstrate that cancer outcomes differ because patients vary in the ways they absorb, distribute, metabolize, and transport drugs across cell membranes.
Individual variations in genes that regulate these biologic processes may not only affect the effectiveness of the drug, but also can result in adverse side effects.
The findings are reported in the current issue of the research journal BMC Medicine.
Source: ANI
RAS/SK
Liver Cancer - Animation
Liver is the largest organ inside the human body. It performs 500 different functions and processes 720 liters of blood per day. The important functions of the liver, the development of liver cancer and it's symptoms are presented in this interactive.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Genetics & Stem Cells News
Relapsing-remitting multiple sclerosis has been successfully treated using autologous hematopoietic stem cell therapy.
Innovative discoveries in male hair loss research uncover uncommon genetic variants tied to it.
Researchers achieved a significant milestone in uncovering the genetic basis of dilated cardiomyopathy in Dobermanns.
Groundbreaking gene therapy for genetic beta thalassemia is now accessible as a treatment to a patient post-FDA approval.
Thymic stem cells actively participate in their environment by generating extracellular matrix proteins, essentially forming their own support system.
